Revival of physostigmine - a novel HPLC assay for simultaneous determination of physostigmine and its metabolite eseroline designed for a pharmacokinetic study of septic patients.
Nadine Pinder, Johannes B Zimmermann, Stefan Hofer, Thorsten Brenner, Markus A Weigand, Ute Gubbe, Torsten Hoppe-Tichy, Stefanie Swoboda
文献索引:Clin. Chem. Lab Med. 53 , 1259-64, (2015)
全文:HTML全文
摘要
Physostigmine, commonly used as an antidote in anticholinergic poisoning, is reported to have additional pharmacological effects, such as activation of the cholinergic anti-inflammatory pathway in sepsis models. Due to the narrow therapeutic range of physostigmine and its metabolite eseroline, however, the plasma concentrations of these substances need to be determined so as to understand their effect and ensure safety in the treatment of septic patients.To determine physostigmine and its metabolite eseroline, a rapid and sensitive high performance liquid chromatography (HPLC) method has been developed and validated. Spiked plasma samples were cleaned up and concentrated using a simple liquid-liquid extraction (LLE) procedure with N-methylphysostigmine as internal standard. Separation was achieved using reversed-phase HPLC on a Kinetex C18 column with gradient elution and fluorescence detection (254 nm excitation/355 nm emission).LLE produced clean extracts and a mean recovery of 80.3% for eseroline and 84.9% for physostigmine. The HPLC assay revealed a limit of detection (LOD) of 0.025 ng/mL and a lower limit of quantification (LLOQ) of 0.05 ng/mL for both analytes. Linearity was observed at 0.05-10.0 ng/mL (r²>0.999). Intra- and inter-day precision ranged from 0.7% to 6.6%, and intra- and inter-day accuracy 97.5%-110.0%.The presented method is useful for human drug level monitoring of physostigmine and eseroline in accordance with current guidelines. Remarkably low plasma concentrations can be quantified after LLE with gradient elution and fluorescence detection, making this a suitable method for pharmacokinetic studies in a clinical setting.
相关化合物
相关文献:
2015-04-13
[Biomacromolecules 16(4) , 1382-9, (2015)]
2015-04-01
[Appl. Environ. Microbiol. 81(7) , 2274-83, (2015)]
2014-12-01
[J. Endocrinol. 223(3) , 241-53, (2014)]
2014-12-29
[Small 10(24) , 5126-36, (2014)]
2014-10-01
[Biochim. Biophys. Acta 1851(2) , 152-62, (2015)]